VRA Vera Bradley, Inc. Insider Trading

CEO Ian Bickley bought 28,901 shares of VRA at $3.87 (2026-06-12); prior VRA buys returned +73.9% and +22.6% at 90 days.

Ian Bickley, CEO, purchased 28,901 shares at $3.87 on 2026-06-12, expanding his holdings by 27.1% to 135,623 shares. His two prior buys at VRA were both well-timed at the 90-day mark, with the 2025-12-12 purchase returning +73.9% and the 2025-06-12 purchase returning +22.6% over 90 days. However, this buy signal occurs against fundamental headwinds: the company reported a net loss of $-4.8M in its most recent quarter, annual revenue contracted 27.5% year-over-year, and the stock is currently priced 18.2% below its 52-week high despite a recent 30-day gain of 10.5%. The pattern of repeated CEO purchases at VRA stands out, but the deteriorating revenue base and ongoing losses create material uncertainty about whether this accumulation signals conviction or reflects other non-trading considerations.

Director Andrew Meslow buys 24,926 shares of VRA at $3.73; 3 prior VRA buys all returned +21.6% to +80.4% over 90 days

Andrew Meslow (Director) purchased 24,926 shares at $3.73, expanding his holdings from 625,074 to 650,000 shares. This represents a continuation of his buying pattern at VRA: his three prior purchases at this ticker on 2025-12-15, 2025-12-12, and 2025-06-12 all generated positive 90-day returns ranging from +21.6% to +80.4%, with all 3 of 3 prior buys well-timed at the 90-day mark. The current price of $3.59 sits 18.2% below the 52-week high and +10.5% above the 30-day price, though the company faces fundamental headwinds: annual revenue declined 27.5%, the latest quarter produced $-4.8M in net income, and the company was unprofitable over its most recent full fiscal year. The insider's demonstrated ability to identify profitable entry points at this specific ticker is notable, though it occurs against a backdrop of deteriorating operational results.

VRA director Bickley buys 53,000 shares at $1.94 amid -66.0% decline from 52-week high.

Bickley Ian, a director of Vera Bradley, purchased 53,000 shares at $1.94 on 2025-12-12, expanding his holdings to 841,629 shares post-transaction, a net increase of 6.7% relative to his pre-transaction holdings of 788,629 shares. This purchase occurs at a price substantially below the 52-week high of $5.38, with the stock currently trading at $1.83, representing a -66.0% decline from the year's peak and a -29.9% drop over the prior 30 days. The company itself faces material headwinds: it generated negative net income of $-12.4M in its latest quarter, reported annual revenue growth of -21.0%, and remains unprofitable on a full-year basis, with a market cap of only $51.2M. At the same ticker, Bickley's prior buy in June 2025 delivered a 90-day return of +22.6%, suggesting favorable timing on that occasion; however, the current transaction occurs in a substantially weakened macro context for the company and would require similar turnaround momentum to validate similar timing success.

Director Meslow Andrew bought 300,000 shares for $590,205 ($1.97 blended avg) across 2 transactions, doubling VRA holdings to 600,000 shares

Director Andrew Meslow executed 2 separate purchases totaling 300,000 shares for $590,205, raising his stake from 300,000 to 600,000 shares—a 100% increase in position size. The blended average purchase price of $1.97 sits above the current price of $1.83 and substantially below the 52-week high of $5.38. This accumulation occurs while Vera Bradley reports deteriorating fundamentals: annual revenue declined 21.0%, the company posted a net loss of $12,365,000 in the latest quarter, and the stock is down 29.9% over 30 days and 66.0% from its 52-week high. His prior purchase at this ticker in June 2025 delivered a 21.6% 90-day return, establishing a pattern of well-timed purchases; however, the current macroeconomic and operational environment—unprofitability and sharp revenue contraction—introduces material context distinct from his prior favorable outcome at VRA.

Vera Bradley Director Bickley buys 53.7K shares at $1.86, more than doubling stake, as stock trades -77.5% from 52-week high.

Director Ian Bickley purchased 53,722 shares at $1.86 on 2025-06-12, expanding his holdings from 39,906 shares to 93,628 shares—a +134.6% increase. The transaction occurred while the stock trades at $1.78, down -77.5% from its 52-week high of $7.90 and down -27.6% over the prior 90 days. The company's recent fundamentals are materially strained: latest-quarter revenue stands at $51,652,000, but net income was $-33,460,000, and annual revenue growth has contracted -21.0%. Bickley's four prior open-market sells across his full cross-ticker history generated a well-timed rate of 0.00%, indicating no historical pattern of successful exit timing. The purchase represents a discretionary accumulation at depressed absolute price levels amid operational headwinds, but offers limited signal regarding forward direction given the company's negative profitability trajectory and the insider's weak prior timing track record.

Director Meslow buys 253.1K VRA shares at $1.88 (+539.6% of prior holdings) amid -21.0% annual revenue decline and -$33.5M net loss

Andrew Meslow, a director at Vera Bradley, purchased 253,094 shares at $1.88, expanding his holdings to 300,000 shares from 46,906 shares—a 539.6% increase in position size. This substantial accumulation occurs amid significant operational headwinds: the company reported -21.0% annual revenue decline and a full-year net income of $-33,460,000, with the latest quarterly net income at $-33.5M. The current stock price of $1.78 is -77.5% from the 52-week high of $7.90 and down -27.6% over 90 days, suggesting the director is purchasing into a materially depressed valuation relative to its recent trading range. The scale of this position increase—committing $474,551.25 to establish a 300K-share stake in a $49.7M market-cap company—represents a meaningful capital deployment by an insider during a period of operational and stock-price distress.